Benjamin Halladay is Chief Financial Officer of Esperion Therapeutics, Inc.. Currently has a direct ownership of 474,473 shares of ESPR, which is worth approximately $555,133. The most recent transaction as insider was on Jun 17, 2025, when has been sold 7,229 shares (Common Stock) at a price of $1.15 per share, resulting in proceeds of $8,313. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 474K
1.5% 3M change
94.51% 12M change
Total Value Held $555,133

Benjamin Halladay Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 17 2025
SELL
Open market or private sale
$8,313 $1.15 p/Share
7,229 Reduced 1.5%
474,473 Common Stock
Apr 17 2025
SELL
Open market or private sale
$7 $0.96 p/Share
8 Reduced 0.0%
481,702 Common Stock
Mar 18 2025
SELL
Open market or private sale
$5,231 $1.48 p/Share
3,535 Reduced 0.73%
481,710 Common Stock
Mar 14 2025
BUY
Grant, award, or other acquisition
-
238,000 Added 32.91%
485,245 Common Stock
Feb 19 2025
SELL
Open market or private sale
$20 $1.86 p/Share
11 Reduced 0.0%
240,671 Common Stock
Jan 17 2025
SELL
Open market or private sale
$20 $2.27 p/Share
9 Reduced 0.0%
240,682 Common Stock
Dec 17 2024
SELL
Open market or private sale
$7,852 $2.42 p/Share
3,245 Reduced 1.33%
240,691 Common Stock
Mar 14 2024
BUY
Grant, award, or other acquisition
-
170,000 Added 41.07%
243,936 Common Stock
Mar 14 2023
BUY
Grant, award, or other acquisition
-
9,200 Added 11.07%
73,936 Common Stock
Dec 09 2022
BUY
Grant, award, or other acquisition
-
44,000 Added 40.83%
63,771 Common Stock
BH

Benjamin Halladay

Chief Financial Officer
Ann Arbor, MI

Track Institutional and Insider Activities on ESPR

Follow Esperion Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ESPR shares.

Notify only if

Insider Trading

Get notified when an Esperion Therapeutics, Inc. insider buys or sells ESPR shares.

Notify only if

News

Receive news related to Esperion Therapeutics, Inc.

Track Activities on ESPR